Polymorphisms in the interferon regulatory factor 5 (IRF5) gene have been consistently replicated and shown to confer risk for or protection from the development of systemic lupus erythematosus (SLE). IRF5 expression is significantly upregulated in SLE patients and upregulation associates with IRF5-SLE risk haplotypes. IRF5 alternative splicing has also been shown to be elevated in SLE patients. Given that human IRF5 exists as multiple alternatively spliced transcripts with distinct function(s), it is important to determine whether the IRF5 transcript profile expressed in healthy donor immune cells is different from that expressed in SLE patients. Moreover, it is not currently known whether an IRF5-SLE risk haplotype defines the profile of IRF5 transcripts expressed. Using standard molecular cloning techniques, we identified and isolated 14 new differentially spliced IRF5 transcript variants from purified monocytes of healthy donors and SLE patients to generate an IRF5 variant transcriptome. Next-generation sequencing was then used to perform in-depth and quantitative analysis of full-length IRF5 transcript expression in primary immune cells of SLE patients and healthy donors by next-generation sequencing. Evidence for additional alternatively spliced transcripts was obtained from de novo junction discovery. Data from these studies support the overall complexity of IRF5 alternative splicing in SLE. Results from next-generation sequencing correlated with cloning and gave similar abundance rankings in SLE patients thus supporting the use of this new technology for in-depth single gene transcript profiling. Results from this study provide the first proof that 1) SLE patients express an IRF5 transcript signature that is distinct from healthy donors, 2) an IRF5-SLE risk haplotype defines the top four most abundant IRF5 transcripts expressed in SLE patients, and 3) an IRF5 transcript signature enables clustering of SLE patients with the H2 risk haplotype.
References
[1]
Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358: 929–939.
[2]
Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA (2010) Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol 6: 461–479.
[3]
Deng Y, Tsao BP (2010) Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 6: 683–692.
[4]
Sigurdsson S, Nordmark G, Harald Goring HH, Lindroos K, Wiman C, et al. (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76: 528–537.
[5]
Demirci FY, Manzi S, Ramsey-Goldman R, Minster RL, Kenney M, et al. (2006) Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet 71: 308–311.
[6]
Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K, et al. (2007) Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 16: 579–591.
[7]
Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550–555.
[8]
Kozyrev SV, Lewen S, Reddy PM, Pons-Estel B (2007) Argentine Collarborative Group, et al (2007) Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 56: 1234–1241.
[9]
Shin HD, Sung YK, Choi CB, Lee SO, Lee HW, et al.. (2007) Replication of genetic effects of interferon regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis Res Ther 9, R32.
[10]
Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 104: 6758–6763.
[11]
Barnes BJ, Moore PA, Pitha PM (2001) Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes J Biol Chem. 276: 23382–23390.
[12]
Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, et al. (2005) The Interferon Regulatory Factor, IRF-5, Is a Central Mediator of Toll-like Receptor 7 Signaling. J Biol Chem 280: 17005–17012.
[13]
Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, et al. (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-Like Receptors. Nature 434: 243–249.
[14]
Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, et al. (2007) Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 104: 3402–3407.
[15]
Feng D, Stone RC, Eloranta ML, Sangster-Guity N, Nordmark G, et al. (2010) Genetic variants and disease-associated factors contribute to enhanced IRF-5 expression in blood cells of systemic lupus erythematosus patients. Arthritis Rheum 62: 562–573.
[16]
Sigurdsson S, Goring HHH, Kristjandsdottir G, Milani L, Nordmark G, et al. (2008) Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17: 872–881.
[17]
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK (2007) High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 56: 3995–4004.
[18]
Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, et al. (2008) Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum 58: 2481–2487.
[19]
Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, et al. (2005) Two distinct promoters regulate the alternative-spliced human Interferon regulatory factor-5 variants: Multiple variants with distinct cell-type specific expression, localization, regulation and function. J Biol Chem 280: 21078–90.
[20]
Barnes BJ, Kellum MJ, Field AE, Pitha PM (2002) Multiple regulatory domains of IRF-5 control activation, cellular localization and induction of chemokines that mediate T-lymphocyte recruitment. Mol Cell Biol 22: 5721–5740.
[21]
Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, et al. (2004) Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 279: 45194–45207.
[22]
Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM (2003) Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 63: 6424–6431.
[23]
Hu G, Mancl M, Barnes BJ (2005) Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 65: 7403–7412.
[24]
Couzinet A, Tamura K, Chen HM, Nishimura K, Wang Z, et al. (2008) A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci U S A 105: 2556–2561.
[25]
Hu G, Barnes BJ (2009) IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J Biol Chem 284: 2767–2777.
[26]
Feng D, Sangster-Guity N, Stone R, Korczeniewska J, Mancl ME, et al. (2010) Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol 185: 6003–6012.
[27]
Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, et al. (2007) Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 178: 6876–6885.
[28]
Paun A, Reinert JT, Jiang Z, Medin C, Balkhi MY, et al. (2008) Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J Biol Chem 283: 14295–14308.
Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, et al. (2003) Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 74: 1125–1138.
[31]
Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, et al. (2010) IFN regulatory factor 5 is required for disease development in the FcgammaRIIB？/？Yaa and FcgammaRIIB？/？ mouse models of systemic lupus erythematosus. J Immunol 184: 796–806.
[32]
Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K (2010) Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci USA 107: 10154–10159.
[33]
Tada Y, Kondo S, Aoki S, Koarada S, Inoue H, et al. (2011) Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice. Arthritis Rheum 63: 738–748.
[34]
Shen H, Panchanathan R, Rajavelu P, Duan X, Gould KA, et al. (2010) Gender-dependent expression of murine Irf5 gene: implications for sex bias in autoimmunity. J Mol Cell Biol 2: 284–290.
[35]
Rullo OJ, Woo JM, Wu H, Hoftman AD, Maranian P, et al. (2010) Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann Rheum Dis 69: 611–617.
[36]
Kozyrev SV, Alarcon-Riquelme ME (2007) The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 40: 591–601.
[37]
Stone RC, Feng D, Deng J, Singh S, Yang L, et al. (2012) Interferon regulatory factor 5 activation in monocytes of SLE patients is triggered by circulating autoantigens independent of type I IFN. Arthritis Rheum 64: 788–798.
[38]
Sambrook J, Russell DW (2001) Preparation of cDNA libraries and gene identification. In: Molecular Cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, 11.69–11.70.
[39]
Turro E, Su SY, Goncalves A, Coin LJ, Richardson S, et al. (2011) Haplotype and isoform specific expression estimation using multi-mapping RNA-seq reads. Genome Biol 12: R13.
Griffith M, Griffith OL, Mwenifumbo J, Goya R, Morrissy AS, et al. (2010) Alternative expression analysis by RNA sequencing. Nature Methods 7: 843–847.
[43]
Lauwerys BR, Van Snick J, Houssiau FA (2002) Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 11: 384–387.
[44]
Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, et al. (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147: 117–123.
[45]
Aringer M, Smolen JS (2003) SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 5: 172–177.
[46]
Rogers S, Wells R, Rechsteiner M (1986) Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234: 364–368.
[47]
Shumway SD, Maki M, Miyamoto S (1999) The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J Biol Chem 274: 30874–30881.
[48]
Jiang X, Coffino P, Li X (2004) Development of a method for screening short-lived proteins using green fluorescent protein. Genome Biol 5: R81.
[49]
Corish P, Tyler-Smith C (1999) Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 12: 1035–1040.
[50]
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621–628.
[51]
Hiller D, Jiang H, Xu W, Wong W (2009) Identifiability of isoform deconvoluation from junction arrays and RNA-Seq. Bioinformatics 25: 3056–3059.
[52]
Jiang H, Wong WH (2009) Statistical inferences for isoform expression in RNA-Seq. Bioinformatics 25: 1026–1032.
[53]
Li B, Ruotti V, Stewart RM, Thomson JA, Dewey CN (2010) RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics 26: 493–500.
[54]
Roberts A, Pimentel H, Trapnell C, Pachter L (2011) Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 27: 2325–2329.
[55]
Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, et al. (2004) Genetic analysis of genome-wide variation in human gene expression. Nature 430: 743–747.
[56]
Alonso-Perez E, Suarez-Gestal M, Calaza M, Kwan T, Majewski J, et al. (2011) Cis-regulation of IRF5 expression is unable to fully account for systemic lupuserythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. Arthritis & Therap 13: R80.
[57]
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079.
[58]
Jarvinen TM, Hellquist A, Zucchelli M, Koskenmies S, Panelius J, et al. (2012) Replication of genome-wide association study identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population. Rheumatology 51: 87–92.
[59]
Barnes BJ, Field A, Pitha-Rowe PM (2003) Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 278: 16630–16641.
[60]
Cheng TF, Brzostek S, Ando O, Van Scoy S, Kumar KP, et al. (2006) Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J Immunol 176: 7462–7470.
[61]
Langmead B (2010) Aligning short sequencing reads with Bowtie. Curr Protoc Bioinformatics Chapter 11, Unit 11 7.
[62]
Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25.
[63]
Burset M, Seledtsov IA, Solovyev VV (2000) Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucl Acids Res 28: 4364–4375.
[64]
Houseley J, Tollervey D (2010) Apparent non-canonical trans-splicing is generated by reverse transcriptase in vitro. PLoS ONE 5(8): e12271.
[65]
Robinson JY, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative Genomics Viewer. Nature Biotechnology 29: 24–26.
